United States

AFFO (TTM)

AFFO/share (TTM)

AFFO/share Guidance

AFFO (Quarter)

AFFO/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/AFFO

Size (ft²)

Occupancy

The Company is a fully integrated REIT primarily focused on the ownership, acquisition, development and management of
retail properties net leased to industry leading tenants.

Agree Realty

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

As a long-term debt issuer, ADC is classified as investment grade

Period: 2023 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 13/15,
Adjusted FFO/share Growth: 18/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2026 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2026 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2026 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's Adjusted FFO

Adjusted FFO Growth

Assessment of recent increases in Adjusted FFO per share, indicating profitability

Adjusted FFO/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

Initiated GLP toxicology studies of lead TROP2-targeted ADC AKTX-101 to enable planned Phase 1 trial in mid-2027 New preclinical findings demonstrate anti-tumor activity in urothelial cancer models resistant to currently approved ADC therapies, reinforcing the potential of novel PH1 payload for patients relapsing on current ADC therapies Collaboration with Whitehawk Therapeutics on novel dual payloads emphasizes PH1 payload's strategic partnering opportunities Strengthened balance sheet with approximately $3 million in proceeds from warrant exercises, ending the quarter with $5.7 million in cash TAMPA, Fla. and LONDON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today reported financial results for the third quarter ended September 30, 2026, and highlighted significant progress advancing its proprietary PH1 payload platform toward Phase 1 clinical development.

Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform

Three tickers make this retirement paycheck easy to run, but one of them already cut its dividend and carries the biggest slice of the income. What happens to the monthly deposit if that board cuts again?

How a 67-Year-Old Collects $4,750 a Month From Just Three Tickers: DIVO, ADC, and BXSL

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.271 per common share. The monthly dividend reflects an annualized dividend amount of $3.252 per common share, representing a 3.4% increase over the annualized dividend amount of $3.144 per common share from the fourth quarter of 2025. The dividend is payable December 14, 2026 to stockholder.

Agree Realty Declares Monthly Common and Preferred Dividends

Your bills show up every month, but most dividend checks only arrive four times a year. Three monthly payers promise to close that gap, though one of them carries a hidden catch that could shrink part of the paycheck.

3 Monthly Dividend Stocks That Could Help Pay Your Retirement Bills

Third quarter 2026 net product revenue of $21 million; cash and cash equivalents of $189.2 million as of September 30, 2026 Strategic financial restructuring strengthens balance sheet, extending expected cash runway into 2029 Abstracts accepted for presentation at ASH 2026, highlighting ZYNLONTA's potential across multiple B-cell malignancies Tanabe's marketing authorization application filing and sublicensing in Japan support anticipated regulatory and commercial milestones for ADC Therapeutics LAUSANNE, Switzerland, Nov. 9, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported full financial results for the third quarter ended September 30, 2026, and provided recent operational updates. "During the third quarter, we made meaningful progress toward strengthening ADC Therapeutics' balance sheet and increasing strategic optionality while advancing clinical opportunities for ZYNLONTA®," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.

ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates

Two monthly-paying REITs look nearly identical on paper, yet one retiree is betting her income on swapping a giant for a smaller rival. What does she gain, what does she give up, and does her paycheck survive?

A 70-Year-Old Swapped O for ADC in a $1.03 Million Income Portfolio. Here’s What Happened to Her $5,650 Monthly Paycheck

Converting everything at once sounds like the clean way to escape future taxes, but it may hand the IRS a bill hundreds of thousands of dollars larger than necessary. A 66-year-old has one calendar deadline, and the smarter path has a catch.

How Much of a $1.15 Million IRA Should a 66-Year-Old Convert to Roth to Collect $5,900 a Month Tax-Free?

ADC Therapeutics NYSE: ADCT outlined new lymphoma data and plans for further studies of its cancer drug ZYNLONTA, while reporting preliminary third-quarter sales of approximately $21 million and an expected cash runway into 2029.

ADC Therapeutics Reports Strong Lymphoma Responses, Plans Phase III Study

Most dividend stocks pay quarterly, leaving retirees to juggle bills against an awkward schedule.

4 Monthly Dividend Stocks That Could Pay You Like Clockwork in Retirement

ZYNLONTA data to be featured across 5 oral presentations and multiple posters Phase 1b LOTIS-7 abstract data demonstrates an 88.7% ORR and 75.3% CR with ZYNLONTA plus glofitamab across the 97 efficacy-evaluable r/r DLBCL patients Phase 2 marginal zone lymphoma IIT abstract shows robust and durable 93% ORR and 74.4% CRR with ZYNLONTA monotherapy Company to host conference call today at 4:15 p.m. EST LAUSANNE, Switzerland, Nov. 4, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced new and updated data from the ZYNLONTA® (loncastuximab tesirine-lpyl) clinical program will be shared across multiple abstracts, including five oral presentations, at the 68th American Society of Hematology (ASH) Annual Meeting taking place December 12–15, 2026, in New Orleans, Louisiana.

ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program

Most dividend stocks make you wait three months between payments, but a small group of NYSE companies cut those checks every single month and keep raising the amount. Three of them clear every safety bar worth checking.

Realty Income Just Raised Its Dividend Again. Here Are 2 More Monthly Payers

LAUSANNE, Switzerland, Nov. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two upcoming investor conferences in November: Guggenheim Third Annual Healthcare Innovation Conference Date: Tuesday, November 10, 2026Presentation Time: 1:30 p.m. ESTFormat: Fireside ChatSpeaker: Ameet Mallik, Chief Executive OfficerLocation: Boston, MATo register for the webcast, click here.

ADC Therapeutics to Present at November Investor Conferences

HAYWARD, Calif.--(BUSINESS WIRE)-- #biotechnology--Aarvik Therapeutics (Aarvik), an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce important updates to its partnership efforts. Dosing of the first patient in a Phase 1 trial in the US for AV-P138-ADC (ARR-002) was recently announced by Aarvik's research collaboration partner, ArriVent Biopharma, Inc. (ArriVent; Nasdaq: AVBP). AV-P138-ADC (ARR-002) is the first MUTTA™-based ADC.

Aarvik Therapeutics Announces Milestone Achievement, Partnership Update, and Presentations on MUTTA™ and AQUALINK™ Platforms at the 17th Annual WADC Conference

LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on November 2, 2026. ("Grant").

ADC Therapeutics Announces New Employee Inducement Grant

LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company will report full financial results for the third quarter of 2026 through a press release on Monday, November 9, 2026. The press release will be available in the News section of the Company's website, https://ir.adctherapeutics.com/news.

ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026

Long-term Treasury yields just pulled back sharply, and net-lease REITs stand to benefit more than almost any other corner of real estate.

The 10-Year Treasury Yield Fell 33 Basis Points. Here Are 5 Net-Lease REITs to Watch

Two monthly dividend REITs both raised guidance this year, but one is charging into data centers while the other is pulling back on deals to guard its balance sheet.

Realty Income and Agree Realty Both Raised Guidance. Which Dividend Looks Stronger?

Presentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing along with immune activation

Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit

Licensing partner, Tanabe Pharma, filed for Japanese approval of ZYNLONTA (MT-2111) for relapsed or refractory DLBCL based on encouraging Japanese Phase 1/2 clinical results Tanabe Pharma entered into exclusive sublicensing agreement with Nippon Shinyaku, bringing established Japanese oncology expertise and commercial capabilities to support potential introduction in Japan Supports anticipated regulatory and commercial milestones for ADC Therapeutics LAUSANNE, Switzerland, Oct. 29, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that its Japanese licensing partner, Tanabe Pharma Corporation (formerly Mitsubishi Tanabe Pharma Corporation), filed a marketing authorization application with Japan's Ministry of Health, Labor and Welfare on October 29, 2026, for ZYNLONTA® (loncastuximab tesirine-lpyl) to treat patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. In addition, Tanabe Pharma has entered into an exclusive sublicensing agreement with Nippon Shinyaku Co., Ltd.

ADC Therapeutics Announces ZYNLONTA® Updates in Japan

Generating over ten thousand dollars a month from a portfolio sounds like a retirement fantasy, but a specific blend of seven holdings makes the math surprisingly concrete. The tricky part is knowing which of those income streams you can actually count on when rates shift or markets get volatile.

How Large Does Your Portfolio Need to Be to Generate $10,300 a Month?

A 10% yield sounds like it solves the $6,400 monthly target with far less capital, but two of the three tests that expose a yield trap can disqualify a holding before you ever collect a check.

How Do You Tell a Yield Trap From a Real $6,400-a-Month Dividend Portfolio?

Generating nearly $100,000 a year in dividend income sounds impossible without a massive nest egg, but the capital you actually need swings wildly depending on where you invest and what risks you are willing to absorb.

How to Build $8,300 a Month in Dividend Income Without Owning a Single Bond

Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca's sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant a

Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01

NEWTOWN SQUARE, Pa., Oct. 25, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced initial encouraging Phase 1 results for ARR-217, (MRG007), a cadherin-17 (CDH17)-targeting antibody-drug conjugate (ADC) developed in partnership with Lepu Biopharma Co., Ltd., in patients with gastrointestinal malignancies. The findings were presented as part of an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress 2026.

ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026

Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026PR NewswireGUANGZHOU, C

Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026

[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated inve

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRÎ±-targeting ADC at ESMO 2026PR NewswireINDI

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FR α expression levels Clinical activity with Sofe-M was maintained even in patients with prior PARP inhibitor exposure, patients who typically experience poor outcomes with platinum-based chemotherapy Sofe-M is currently being studied in both platinum-sensitive and platinum-resistant ovarian cancer in multiple Phase 3 studies as part of the FRAmework-01 master protocol INDIANAPOLIS, Oct. 24, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its investigational folate receptor alpha (FRα) antibody-drug conjugate (ADC) sofetabart mipitecan (Sofe-M) plus bevacizumab achieved a confirmed objective response rate (cORR) of 79% and a disease control rate (DCR) of 100% in patients with platinum-sensitive ovarian cancer (PSOC). A cORR of 79% or higher was seen in both poly (ADP-ribose) polymerase inhibitor (PARPi)-treated and PARPi-naïve patients.

NEWTOWN SQUARE, Pa., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that initial safety and efficacy data from the Phase 1 (NCT07066657) study of CDH17-targeted ADC ARR-217 (MRG007) in patients with gastrointestinal cancers, will be presented in a rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain, on October 23-27, 2026. ArriVent plans to host a virtual webinar on October 26, 2026 at 8 am ET to discuss the data and ARR-217 program. To register for the event, click here.

ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) an innovation-driven, global biopharma company, today announced that it has entered into a securities purchase agreem

Zai Lab Announces $250 Million Private Placement

Where you hold a dividend portfolio matters almost as much as what you hold, and for one mix of REITs and a BDC generating nearly $45,000 a year, the difference between account types could quietly reshape your retirement math.

An $800,000 Portfolio Pays Nearly $3,800 a Month. How Much Would Taxes Take?

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO.

Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO

MAINZ, Germany, October 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced a clinical trial collaboration and supply agreement with Gilead Sciences Inc. (“Gilead”) to evaluate pumitamig in combination with the TROP2-directed antibody-drug conjugate (“ADC”) sacituzumab govitecan (Trodelvy®) as first-line treatment for patients with locally advanced or metastatic PD-L1 low or negative triple-negative breast cancer (“TNBC”). Pumitamig is an investigational bispecific immunomodulator designed to cooperatively bind to PD-L1 and VEGF-A that is being jointly developed by BioNTech and Bristol Myers Squibb (“BMS”).

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

Agree Realty reduced 2026 investment volume guidance to $1.6 billion. The company's retail portfolio reached 99.8% occupancy in the third quarter.

Agree Realty: 3 Key Takeaways for Long-Term Investors

Agree Realty NYSE: ADC reported third-quarter 2026 core funds from operations and adjusted funds from operations of $1.15 per share, each up 4.9% from the prior-year quarter, while maintaining portfolio occupancy of 99.8%.

What Agree Realty (ADC) Said on Its Q3 Earnings Call

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced results for the quarter ended September 30, 2026. All per share amounts included herein are on a diluted per common share basis unless otherwise stated. Third Quarter 2026 Financial and Operating Highlights: Invested approximately $358 million in 94 retail net lease properties Commenced six development or Developer Funding Platform (“DFP”) projects for total committed capital of approximately.

Agree Realty Corporation Reports Third Quarter 2026 Results

Parking high-yield BDCs and REITs in a taxable account quietly hands the IRS a check every April, and most investors never calculate exactly how much they are giving away each year across their entire portfolio.

A $750,000 Dividend Portfolio Could Lose $13,920 a Year to Taxes. Here's the Roth Alternative

Net lease REITs let you collect rent checks without fixing a single leaky faucet, but not all three of these monthly payers carry the same risks, growth rates, or tenant quality under the hood.

3 Dividend Stocks That Let You Collect Rent Without Becoming a Landlord

Montreal, Quebec--(Newsfile Corp. - October 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® drug-delivery platform, is pleased to announce two significant achievements at World ADC San Diego 2026, held October 12-15: winning the conference's Best Poster Award for its Accum ® -ADC research and leading a main-stage discussion alongside internationally recognized experts in antibody-drug conjugates ("ADCs"). These achievements highlight the growing recognition of Defence's Accum® technology within the global ADC community.

Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast CancerPR NewswireSHANGHAI, O

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer

/C O R R E C T I O N - AbbVie/PR NewswireNORTH CHICAGO, Ill., Oct. 18, 2026In the news release, AbbVie to Present Data at the 2026 European Society for Medical

/C O R R E C T I O N - AbbVie/

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) CongressPR NewswireINDIANAPOLIS, Oct. 18, 2026F

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor PortfolioPR News

AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio

Monthly bills arrive on a schedule that quarterly dividends cannot match, but five stocks pay 12 times a year with yields climbing as high as 6.65%. Two of them carry risks that could quietly shrink your paycheck before you notice.

5 Monthly Dividend Stocks Retirees Should Consider This Month

CEO Abizer Gaslightwala discusses Akari's novel PH1 payload strategy and execution priorities supporting AKTX-101's advancement toward planned Phase 1 clinical development in mid-2027

Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.271 per common share, representing a 1.5% month-over-month increase. The monthly dividend reflects an annualized dividend amount of $3.252 per common share, representing a 3.4% increase over the annualized dividend amount of $3.144 per common share from the fourth quarter of 2025. The divid.

Agree Realty Declares Increased Monthly Common Dividend

Mr. Vat-Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more than $25 billion in aggregate value

Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering

Some REITs pay dividends quarterly, but these five send checks every single month, and their cash flow coverage tells a more interesting story than the yield numbers alone.

Investors Love 5 Dividend Stocks That Pay Dependable Monthly Dividends

VERAXA Biotech presents first in vivo proof-of-concept for BiTAC®-ADC: tumor-selective activation with potent anti-tumor efficacy and improved safety.

VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress

CoreCap Advisors LLC lessened its position in Agree Realty Corporation (NYSE: ADC) by 94.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,213 shares of the real estate investment trust's stock after selling 76,056 shares during the quarter. CoreCap Advisors LLC's

Agree Realty Corporation $ADC Shares Sold by CoreCap Advisors LLC

INITIATED GLP TOXICOLOGY STUDIES OF LEAD TROP2-TARGETED ADC AKTX-101 TO ENABLE PLANNED PHASE 1 TRIAL IN MID-2027 NEW PRECLINICAL FINDINGS DEMONSTRATE ANTI-TUMOR ACTIVITY IN UROTHELIAL CANCER MODELS RESISTANT TO CURRENTLY APPROVED ADC THERAPIES, REINFORCING THE POTENTIAL OF NOVEL PH1 PAYLOAD FOR PATIENTS RELAPSING ON CURRENT ADC THERAPIES COLLABORATION WITH WHITEHAWK THERAPEUTICS ON NOVEL DUAL PAYLOADS EMPHASIZES PH1 PAYLOAD'S STRATEGIC PARTNERING OPPORTUNITIES STRENGTHENED BALANCE SHEET WITH APPROXIMATELY $3 MILLION IN PROCEEDS FROM WARRANT EXERCISES, ENDING THE QUARTER WITH $5.7 MILLION IN CASH TAMPA, FLA. AND LONDON, NOV. 12, 2026 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX) (AKARI OR THE COMPANY), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING ANTIBODY DRUG CONJUGATES (ADCS) WITH A NOVEL RNA SPLICING DISRUPTING PAYLOAD, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2026, AND HIGHLIGHTED SIGNIFICANT PROGRESS ADVANCING ITS PROPRIETARY PH1 PAYLOAD PLATFORM TOWARD PHASE 1 CLINICAL DEVELOPMENT.

AKARI THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND HIGHLIGHTS CONTINUED PROGRESS TOWARD CLINICAL DEVELOPMENT OF DIFFERENTIATED ADC PAYLOAD PLATFORM

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.271 PER COMMON SHARE. THE MONTHLY DIVIDEND REFLECTS AN ANNUALIZED DIVIDEND AMOUNT OF $3.252 PER COMMON SHARE, REPRESENTING A 3.4% INCREASE OVER THE ANNUALIZED DIVIDEND AMOUNT OF $3.144 PER COMMON SHARE FROM THE FOURTH QUARTER OF 2025. THE DIVIDEND IS PAYABLE DECEMBER 14, 2026 TO STOCKHOLDER.

AGREE REALTY DECLARES MONTHLY COMMON AND PREFERRED DIVIDENDS

THIRD QUARTER 2026 NET PRODUCT REVENUE OF $21 MILLION; CASH AND CASH EQUIVALENTS OF $189.2 MILLION AS OF SEPTEMBER 30, 2026 STRATEGIC FINANCIAL RESTRUCTURING STRENGTHENS BALANCE SHEET, EXTENDING EXPECTED CASH RUNWAY INTO 2029 ABSTRACTS ACCEPTED FOR PRESENTATION AT ASH 2026, HIGHLIGHTING ZYNLONTA'S POTENTIAL ACROSS MULTIPLE B-CELL MALIGNANCIES TANABE'S MARKETING AUTHORIZATION APPLICATION FILING AND SUBLICENSING IN JAPAN SUPPORT ANTICIPATED REGULATORY AND COMMERCIAL MILESTONES FOR ADC THERAPEUTICS LAUSANNE, SWITZERLAND, NOV. 9, 2026 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT) TODAY REPORTED FULL FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2026, AND PROVIDED RECENT OPERATIONAL UPDATES. "DURING THE THIRD QUARTER, WE MADE MEANINGFUL PROGRESS TOWARD STRENGTHENING ADC THERAPEUTICS' BALANCE SHEET AND INCREASING STRATEGIC OPTIONALITY WHILE ADVANCING CLINICAL OPPORTUNITIES FOR ZYNLONTA," SAID AMEET MALLIK, CHIEF EXECUTIVE OFFICER OF ADC THERAPEUTICS.

ADC THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATES

ZYNLONTA DATA TO BE FEATURED ACROSS 5 ORAL PRESENTATIONS AND MULTIPLE POSTERS PHASE 1B LOTIS-7 ABSTRACT DATA DEMONSTRATES AN 88.7% ORR AND 75.3% CR WITH ZYNLONTA PLUS GLOFITAMAB ACROSS THE 97 EFFICACY-EVALUABLE R/R DLBCL PATIENTS PHASE 2 MARGINAL ZONE LYMPHOMA IIT ABSTRACT SHOWS ROBUST AND DURABLE 93% ORR AND 74.4% CRR WITH ZYNLONTA MONOTHERAPY COMPANY TO HOST CONFERENCE CALL TODAY AT 4:15 P.M. EST LAUSANNE, SWITZERLAND, NOV. 4, 2026 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED NEW AND UPDATED DATA FROM THE ZYNLONTA (LONCASTUXIMAB TESIRINE-LPYL) CLINICAL PROGRAM WILL BE SHARED ACROSS MULTIPLE ABSTRACTS, INCLUDING FIVE ORAL PRESENTATIONS, AT THE 68THAMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING TAKING PLACE DECEMBER 1215, 2026, IN NEW ORLEANS, LOUISIANA.

ADC THERAPEUTICS ANNOUNCES ABSTRACTS AT THE 68TH ASH ANNUAL MEETING HIGHLIGHTING BREADTH OF ZYNLONTA CLINICAL PROGRAM

LAUSANNE, SWITZERLAND, NOV. 3, 2026 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED PARTICIPATION IN TWO UPCOMING INVESTOR CONFERENCES IN NOVEMBER: GUGGENHEIM THIRD ANNUAL HEALTHCARE INNOVATION CONFERENCEDATE: TUESDAY, NOVEMBER 10, 2026PRESENTATION TIME: 1:30 P.M. ESTFORMAT: FIRESIDE CHATSPEAKER: AMEET MALLIK, CHIEF EXECUTIVE OFFICERLOCATION: BOSTON, MATO REGISTER FOR THE WEBCAST, CLICKHERE.

ADC THERAPEUTICS TO PRESENT AT NOVEMBER INVESTOR CONFERENCES

HAYWARD, CALIF.--(BUSINESS WIRE)-- #BIOTECHNOLOGY--AARVIK THERAPEUTICS (AARVIK), AN INNOVATIVE, ADC-FOCUSED BIOTECHNOLOGY COMPANY DEDICATED TO ENGINEERING PRECISION MEDICINES FOR CANCER THERAPY, IS PLEASED TO ANNOUNCE IMPORTANT UPDATES TO ITS PARTNERSHIP EFFORTS. DOSING OF THE FIRST PATIENT IN A PHASE 1 TRIAL IN THE US FOR AV-P138-ADC (ARR-002) WAS RECENTLY ANNOUNCED BY AARVIK'S RESEARCH COLLABORATION PARTNER, ARRIVENT BIOPHARMA, INC. (ARRIVENT; NASDAQ: AVBP). AV-P138-ADC (ARR-002) IS THE FIRST MUTTA-BASED ADC.

AARVIK THERAPEUTICS ANNOUNCES MILESTONE ACHIEVEMENT, PARTNERSHIP UPDATE, AND PRESENTATIONS ON MUTTA AND AQUALINK PLATFORMS AT THE 17TH ANNUAL WADC CONFERENCE

LAUSANNE, SWITZERLAND, NOV. 2, 2026 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT THE COMPANY HAS MADE A GRANT OF OPTIONS TO PURCHASE AN AGGREGATE OF 17,000 OF THE COMPANY'S COMMON SHARES TO A NEW EMPLOYEE ON NOVEMBER 2, 2026. ("GRANT").

ADC THERAPEUTICS ANNOUNCES NEW EMPLOYEE INDUCEMENT GRANT

LAUSANNE, SWITZERLAND, NOV. 2, 2026 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT THE COMPANY WILL REPORT FULL FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2026 THROUGH A PRESS RELEASE ON MONDAY, NOVEMBER 9, 2026. THE PRESS RELEASE WILL BE AVAILABLE IN THE NEWS SECTION OF THE COMPANY'S WEBSITE, HTTPS://IR.ADCTHERAPEUTICS.COM/NEWS.

ADC THERAPEUTICS TO ANNOUNCE THIRD QUARTER 2026 FINANCIAL RESULTS ON NOVEMBER 9, 2026

PRESENTATION TO EXPLORE THE POTENTIAL OF RNA-SPLICING PAYLOADS TO DRIVE BROAD ANTI-TUMOR EFFECTS THROUGH DIRECT CELL KILLING ALONG WITH IMMUNE ACTIVATION

AKARI THERAPEUTICS TO HIGHLIGHT NOVEL RNA-SPLICING ADC PAYLOAD STRATEGY AT THE 3RD ANNUAL ADC PAYLOAD SUMMIT

LICENSING PARTNER, TANABE PHARMA, FILED FOR JAPANESE APPROVAL OF ZYNLONTA (MT-2111) FOR RELAPSED OR REFRACTORY DLBCL BASED ON ENCOURAGING JAPANESE PHASE 1/2 CLINICAL RESULTS TANABE PHARMA ENTERED INTO EXCLUSIVE SUBLICENSING AGREEMENT WITH NIPPON SHINYAKU, BRINGING ESTABLISHED JAPANESE ONCOLOGY EXPERTISE AND COMMERCIAL CAPABILITIES TO SUPPORT POTENTIAL INTRODUCTION IN JAPAN SUPPORTS ANTICIPATED REGULATORY AND COMMERCIAL MILESTONES FOR ADC THERAPEUTICS LAUSANNE, SWITZERLAND, OCT. 29, 2026 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT ITS JAPANESE LICENSING PARTNER, TANABE PHARMA CORPORATION (FORMERLY MITSUBISHI TANABE PHARMA CORPORATION), FILED A MARKETING AUTHORIZATION APPLICATION WITH JAPAN'S MINISTRY OF HEALTH, LABOR AND WELFARE ON OCTOBER 29, 2026, FOR ZYNLONTA (LONCASTUXIMAB TESIRINE-LPYL) TO TREAT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY. IN ADDITION, TANABE PHARMA HAS ENTERED INTO AN EXCLUSIVE SUBLICENSING AGREEMENT WITH NIPPON SHINYAKU CO., LTD.

ADC THERAPEUTICS ANNOUNCES ZYNLONTA UPDATES IN JAPAN

NEWTOWN SQUARE, PA., OCT. 25, 2026 (GLOBE NEWSWIRE) -- ARRIVENT BIOPHARMA, INC. (COMPANY OR ARRIVENT) (NASDAQ: AVBP), A CLINICAL-STAGE COMPANY DEDICATED TO ACCELERATING THE GLOBAL DEVELOPMENT OF INNOVATIVE BIOPHARMACEUTICAL THERAPEUTICS, TODAY ANNOUNCED INITIAL ENCOURAGING PHASE 1 RESULTS FOR ARR-217, (MRG007), A CADHERIN-17 (CDH17)-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) DEVELOPED IN PARTNERSHIP WITH LEPU BIOPHARMA CO., LTD., IN PATIENTS WITH GASTROINTESTINAL MALIGNANCIES. THE FINDINGS WERE PRESENTED AS PART OF AN ORAL PRESENTATION AT THE 2026 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS 2026.

ARRIVENT ANNOUNCES INITIAL PHASE 1 DATA FOR CDH17-TARGETED ADC ARR-217 IN PATIENTS WITH GASTROINTESTINAL CANCERS AT ESMO CONGRESS 2026

NEWTOWN SQUARE, PA., OCT. 23, 2026 (GLOBE NEWSWIRE) -- ARRIVENT BIOPHARMA, INC. (COMPANY OR ARRIVENT) (NASDAQ: AVBP), A CLINICAL-STAGE COMPANY DEDICATED TO ACCELERATING THE GLOBAL DEVELOPMENT OF INNOVATIVE BIOPHARMACEUTICAL THERAPEUTICS, TODAY ANNOUNCED THAT INITIAL SAFETY AND EFFICACY DATA FROM THE PHASE 1 (NCT07066657) STUDY OF CDH17-TARGETED ADC ARR-217 (MRG007) IN PATIENTS WITH GASTROINTESTINAL CANCERS, WILL BE PRESENTED IN A RAPID ORAL PRESENTATION AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS 2026 TAKING PLACE IN MADRID, SPAIN, ON OCTOBER 23-27, 2026. ARRIVENT PLANS TO HOST A VIRTUAL WEBINAR ON OCTOBER 26, 2026 AT 8 AM ET TO DISCUSS THE DATA AND ARR-217 PROGRAM. TO REGISTER FOR THE EVENT, CLICKHERE.

ARRIVENT TO PRESENT INITIAL PHASE 1 DATA FOR CDH17-TARGETED ADC ARR-217 IN PATIENTS WITH GASTROINTESTINAL CANCERS AT THE ESMO CONGRESS 2026

TOKYO--(BUSINESS WIRE)--DAIICHI SANKYO HIGHLIGHTS ONGOING PROGRESS ACROSS INDUSTRY-LEADING ADC PORTFOLIO WITH NEW RESEARCH UPDATES AT ESMO.

DAIICHI SANKYO HIGHLIGHTS ONGOING PROGRESS ACROSS INDUSTRY-LEADING ADC PORTFOLIO WITH NEW RESEARCH UPDATES AT ESMO

MAINZ, GERMANY, OCTOBER 22, 2026  BIONTECH SE (NASDAQ: BNTX, BIONTECH) TODAY ANNOUNCED A CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH GILEAD SCIENCES INC. (GILEAD) TO EVALUATE PUMITAMIG IN COMBINATION WITH THE TROP2-DIRECTED ANTIBODY-DRUG CONJUGATE (ADC) SACITUZUMAB GOVITECAN (TRODELVY) AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PD-L1 LOW OR NEGATIVE TRIPLE-NEGATIVE BREAST CANCER (TNBC). PUMITAMIG IS AN INVESTIGATIONAL BISPECIFIC IMMUNOMODULATOR DESIGNED TO COOPERATIVELY BIND TO PD-L1 AND VEGF-A THAT IS BEING JOINTLY DEVELOPED BY BIONTECH AND BRISTOL MYERS SQUIBB (BMS).

BIONTECH ADVANCES PHASE 3 CLINICAL TRIAL OF PUMITAMIG IN COMBINATION WITH GILEAD'S TROP2-DIRECTED ADC SACITUZUMAB GOVITECAN IN TRIPLE-NEGATIVE BREAST CANCER

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2026. ALL PER SHARE AMOUNTS INCLUDED HEREIN ARE ON A DILUTED PER COMMON SHARE BASIS UNLESS OTHERWISE STATED. THIRD QUARTER 2026 FINANCIAL AND OPERATING HIGHLIGHTS: INVESTED APPROXIMATELY $358 MILLION IN 94 RETAIL NET LEASE PROPERTIES COMMENCED SIX DEVELOPMENT OR DEVELOPER FUNDING PLATFORM (DFP) PROJECTS FOR TOTAL COMMITTED CAPITAL OF APPROXIMATELY.

AGREE REALTY CORPORATION REPORTS THIRD QUARTER 2026 RESULTS

MONTREAL, QUEBEC--(NEWSFILE CORP. - OCTOBER 19, 2026) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("DEFENCE" OR THE "COMPANY"), A PUBLICLY TRADED BIOTECHNOLOGY COMPANY DEVELOPING NEXT-GENERATION PRECISION ONCOLOGY THERAPEUTICS USING ITS PROPRIETARY ACCUM DRUG-DELIVERY PLATFORM, IS PLEASED TO ANNOUNCE TWO SIGNIFICANT ACHIEVEMENTS AT WORLD ADC SAN DIEGO 2026, HELD OCTOBER 12-15:WINNING THE CONFERENCE'S BEST POSTER AWARD FOR ITS ACCUM  -ADC RESEARCH AND LEADING A MAIN-STAGE DISCUSSION ALONGSIDE INTERNATIONALLY RECOGNIZED EXPERTS IN ANTIBODY-DRUG CONJUGATES ("ADCS"). THESE ACHIEVEMENTS HIGHLIGHT THE GROWING RECOGNITION OF DEFENCE'S ACCUM TECHNOLOGY WITHIN THE GLOBAL ADC COMMUNITY.

DEFENCE THERAPEUTICS WINS BEST POSTER AWARD AND TAKES CENTER STAGE AT WORLD ADC SAN DIEGO 2026, A KEY RECOGNITION IN THE FIELD HIGHLIGHTING THE POTENTIAL OF ITS ACCUM PLATFORM

CEO ABIZER GASLIGHTWALA DISCUSSES AKARI'S NOVEL PH1 PAYLOAD STRATEGY AND EXECUTION PRIORITIES SUPPORTING AKTX-101'S ADVANCEMENT TOWARD PLANNED PHASE 1 CLINICAL DEVELOPMENT IN MID-2027

AKARI THERAPEUTICS CEO HIGHLIGHTS DIFFERENTIATED ADC PAYLOAD STRATEGY AND PATH TOWARD CLINICAL DEVELOPMENT IN NEW CEO CORNER

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.271 PER COMMON SHARE, REPRESENTING A 1.5% MONTH-OVER-MONTH INCREASE. THE MONTHLY DIVIDEND REFLECTS AN ANNUALIZED DIVIDEND AMOUNT OF $3.252 PER COMMON SHARE, REPRESENTING A 3.4% INCREASE OVER THE ANNUALIZED DIVIDEND AMOUNT OF $3.144 PER COMMON SHARE FROM THE FOURTH QUARTER OF 2025. THE DIVID.

AGREE REALTY DECLARES INCREASED MONTHLY COMMON DIVIDEND

MR. VAT-HO'S APPOINTMENT ADDS MORE THAN 20 YEARS OF ONCOLOGY, BIOPHARMA AND CAPITAL MARKETS EXPERIENCE, INCLUDING SENIOR ROLES IN TRANSACTIONS TOTALING MORE THAN $25 BILLION IN AGGREGATE VALUE

AKARI THERAPEUTICS APPOINTS ACCOMPLISHED ONCOLOGY AND ADC DEAL EXECUTIVE VATNAK VAT-HO AS CHIEF BUSINESS OFFICER TO DRIVE STRATEGIC GROWTH AND PARTNERING

VERAXA BIOTECH PRESENTS FIRST IN VIVO PROOF-OF-CONCEPT FOR BITAC-ADC: TUMOR-SELECTIVE ACTIVATION WITH POTENT ANTI-TUMOR EFFICACY AND IMPROVED SAFETY.

VERAXA BIOTECH PRESENTSIN VIVO PROOF-OF-CONCEPT DATA FOR BITAC-ADC TECHNOLOGY AT WORLD ADC CONGRESS

AS AI WORKLOADS INCREASE IN VOLUME AND COMPLEXITY, TEXAS INSTRUMENTS IS DELIVERING THE ESSENTIAL SOLUTIONS NEEDED TO POWER, MONITOR AND OPTIMIZE AI DATA CENTERS NEWS HIGHLIGHTS: TI'S ADC34DSO75 IS THE INDUSTRY'S HIGHEST PERFORMANCE 3 GIGASAMPLES PER SECOND ADC, ENABLING 24/7, LOW-POWER, EVENT-BASED REMOTE MONITORING AT NANOSECOND RESOLUTION  THOUSANDS OF TIMES FASTER THAN WHAT CURRENT SOLUTIONS OFFER. THE LMI800PS IS THE INDUSTRY'S FIRST 800V ISOLATED HOT-SWAP CONTROLLER, REPLACING A COMPLEX DISCRETE SOLUTION REQUIRING FIVE INTEGRATED CIRCUITS WITH A SINGLE HIGH-DENSITY PACKAGE THAT DELIVERS IN-RUSH CURRENT AND POWER PATH PROTECTION.

TI UNVEILS NEW ADC TO ENABLE NANOSECOND-LEVEL TELEMETRY AND MINIMIZE DOWNTIME IN AI DATA CENTERS

$86.6 MILLION PRIVATE PLACEMENT ANNOUNCED, WITH PARTICIPATION FROM NEW AND EXISTING INVESTORS, EXTENDING EXPECTED CASH RUNWAY INTO 2029 HEALTHCARE ROYALTY FINANCING AGREEMENT AMENDED, REMOVING CHANGE-OF-CONTROL PAYMENT SENIOR SECURE LOAN REFINANCED, DECREASING PRINCIPAL TO $50M WITH BULLET PAYMENT IN AUGUST 2029 AND NO MINIMUM LIQUIDITY LAUSANNE, SWITZERLAND, OCT. 8, 2026 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED A COMPREHENSIVE STRATEGIC FINANCIAL RESTRUCTURING DESIGNED TO STRENGTHEN ITS BALANCE SHEET, REDUCE LEVERAGE, AND INCREASE STRATEGIC OPTIONALITY TO MAXIMIZE SHAREHOLDER VALUE WHILE EXTENDING THE EXPECTED CASH RUNWAY INTO 2029. THE STRATEGIC INITIATIVE INCLUDES SECURING NEW EQUITY FINANCING, RESTRUCTURING THE HEALTHCARE ROYALTY (HCR) AGREEMENT, AND REDUCING THE OUTSTANDING LOAN PRINCIPAL.

ADC THERAPEUTICS ANNOUNCES COMPREHENSIVE STRATEGIC FINANCIAL RESTRUCTURING MARKING KEY CAPITAL STRUCTURE IMPROVEMENTS

PATENT DISCLOSES USES BEYOND ADCS, INCLUDING AUTOLOGOUS OR ALLOGENEIC ADOPTIVE CELLULAR IMMUNOTHERAPIES LIKE CAR-T, TREGS OR TIL CELL THERAPIES TAMPA, FLA., OCT. 5, 2026 /PRNEWSWIRE/ -- TUHURA BIOSCIENCES, INC. (NASDAQ:HURA) ("TUHURA" OR THE "COMPANY"), A PHASE 3 IMMUNO-ONCOLOGY COMPANY DEVELOPING NOVEL THERAPEUTICS TO OVERCOME RESISTANCE TO CANCER IMMUNOTHERAPY, TODAY ANNOUNCED THAT THE UNITED STATES PATENT AND TRADEMARK OFFICE HAS ISSUED U.S. PATENT NO.

TUHURA BIOSCIENCES RECEIVES KEY U.S. PATENT FOR ITS GROUNDBREAKING DELTA OPIOID RECEPTOR (DOR) ANTIBODY DRUG CONJUGATE (ADC) TECHNOLOGY

PHASE 1/2 APOLLO GLOBAL CLINICAL TRIAL TO EVALUATE CR-002 IN MULTIPLE SOLID TUMOR TYPES, INCLUDING NON-SMALL CELL LUNG CANCER (NSCLC) AND HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC), ON TRACK TO INITIATE IN THE FOURTH QUARTER OF 2026

CRESCENT BIOPHARMA ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR CR-002, A PD-L1-TARGETED TOPOISOMERASE INHIBITOR ADC, FOR THE TREATMENT OF SOLID TUMORS

MONTREAL, QUEBEC--(NEWSFILE CORP. - OCTOBER 1, 2026) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("DEFENCE" OR THE "COMPANY"), A PUBLICLY TRADED BIOTECHNOLOGY COMPANY DEVELOPING NEXT-GENERATION PRECISION ONCOLOGY THERAPEUTICS USING ITS PROPRIETARY ACCUM PLATFORM, IS PLEASED TO ANNOUNCE ITS PARTICIPATION IN THE 17TH WORLD ADC SAN DIEGO, TAKING PLACE OCTOBER 12-15, 2026, IN SAN DIEGO, CALIFORNIA. WORLD ADC SAN DIEGO IS A LEADING GLOBAL FORUM DEDICATED TO ANTIBODY-DRUG CONJUGATES ("ADCS"), BRINGING TOGETHER LEADERS FROM PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, EMERGING INNOVATORS, ACADEMIA AND THE CLINICAL COMMUNITY TO EXCHANGE SCIENTIFIC INSIGHTS, FOSTER COLLABORATION AND ADVANCE THE DEVELOPMENT OF NEXT-GENERATION ADCS.

DEFENCE THERAPEUTICS TO TAKE THE STAGE AT WORLD ADC SAN DIEGO TO DISCUSS THE NEXT FRONTIER IN ANTIBODY-DRUG CONJUGATES

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT IT WILL RELEASE ITS THIRD QUARTER 2026 OPERATING RESULTS AFTER THE MARKET CLOSES ON TUESDAY, OCTOBER 20, 2026. A CONFERENCE CALL TO DISCUSS THE COMPANY'S OPERATING RESULTS IS SCHEDULED FOR WEDNESDAY, OCTOBER 21, 2026, AT 9:00 AM ET. INTERESTED PARTIES AND SHAREHOLDERS MAY ACCESS THE CALL VIA TELECONFERENCE OR WEBCAST: TELECONFERENCE: USA TOLL FREE (833) 461-5787 INTERNATIONAL (626) 884-3.

AGREE REALTY ANNOUNCES THIRD QUARTER 2026 EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS OPERATING PARTNERSHIP, AGREE LIMITED PARTNERSHIP (THE OPERATING PARTNERSHIP), PRICED A PUBLIC OFFERING OF $400 MILLION OF ITS 5.650% SENIOR UNSECURED NOTES DUE 2036 (THE NOTES). THE PUBLIC OFFERING PRICE FOR THE NOTES WAS 98.497% OF THE PRINCIPAL AMOUNT FOR AN EFFECTIVE YIELD TO MATURITY OF 5.849%. THE NOTES WILL BE SENIOR UNSECURED OBLIGATIONS OF THE OPERATING PARTNERSHIP, GUARA.

AGREE REALTY ANNOUNCES PRICING OF $400 MILLION OF 5.650% SENIOR UNSECURED NOTES DUE 2036

PTK7 EXPRESSION REMAINED STABLE FOLLOWING STANDARD-OF-CARE THERAPIES, SUPPORTING ITS RELEVANCE AS A TARGET IN SECOND- OR LATER-LINE EGFR NSCLC FINDINGS REINFORCE THE SCIENTIFIC RATIONALE FOR HWK-007, WHITEHAWK'S NEXT-GENERATION PTK7-DIRECTED ADC CURRENTLY IN PHASE 1 DEVELOPMENT MORRISTOWN, N.J., SEPT. 13, 2026 /PRNEWSWIRE/ -- WHITEHAWK THERAPEUTICS, INC.(NASDAQ: WHWK), A CLINICAL-STAGE ONCOLOGY THERAPEUTICS COMPANY APPLYING ADVANCED TECHNOLOGIES TO ESTABLISHED TUMOR BIOLOGY TO EFFICIENTLY DEVELOP IMPROVED ANTIBODY DRUG CONJUGATE (ADC)CANCER TREATMENTS, TODAY ANNOUNCED THE PRESENTATION OF TWO REAL-WORLD ANALYSES SUPPORTING PROTEIN TYROSINE KINASE 7 (PTK7) AS A DURABLE AND CLINICALLY RELEVANT ADC TARGET IN PATIENTS WITH PRETREATED, EGFR WILD-TYPE NON-SMALL CELL LUNG CANCER (NSCLC).

WHITEHAWK THERAPEUTICS PRESENTS REAL-WORLD ANALYSES SUPPORTING PTK7 AS A DURABLE ADC TARGET IN EGFR WILD-TYPE NON-SMALL CELL LUNG CANCER AT WCLC 2026

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE "COMPANY") TODAY ANNOUNCED THE RELEASE OF ITS 2025 SUSTAINABILITY REPORT. THE REPORT HIGHLIGHTS THE COMPANY'S ENVIRONMENTAL, SOCIAL AND GOVERNANCE ("ESG") INITIATIVES AND IS ALIGNED WITH THE ISSB IFRS S1 AND S2 DISCLOSURE STANDARDS. "I'M VERY PLEASED TO SHARE OUR SIXTH ANNUAL SUSTAINABILITY REPORT," SAID PETER COUGHENOUR, CHIEF FINANCIAL OFFICER. DURING 2025, WE DEEPENED OUR ENGAGEMENT WITH TENANTS ACROSS OUR PORTFOLIO.

AGREE REALTY PUBLISHES SIXTH ANNUAL SUSTAINABILITY REPORT

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.267 PER COMMON SHARE. THE MONTHLY DIVIDEND REFLECTS AN ANNUALIZED DIVIDEND AMOUNT OF $3.204 PER COMMON SHARE, REPRESENTING A 4.3% INCREASE OVER THE ANNUALIZED DIVIDEND AMOUNT OF $3.072 PER COMMON SHARE FROM THE THIRD QUARTER OF 2025. THE DIVIDEND IS PAYABLE OCTOBER 14, 2026 TO STOCKHOLDERS O.

Agree Realty

ADC

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ADC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ADC